financetom
Business
financetom
/
Business
/
Immatics' Q1 Loss Narrows. Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Immatics' Q1 Loss Narrows. Revenue Rises
May 14, 2024 4:59 AM

07:32 AM EDT, 05/14/2024 (MT Newswires) -- Immatics ( IMTX ) reported a Q1 net loss Tuesday of 0.04 euros ($0.043) per diluted share, narrowing from a loss of 0.26 euros a year earlier.

Three analysts polled by Capital IQ expected a loss of 0.27 euros.

Revenue from collaboration agreements for the quarter ended March 31 was 30.3 million euros, up from 9.8 million euros a year earlier.

Analysts surveyed by Capital IQ expected 20.5 million euros.

Price: 11.11, Change: +0.11, Percent Change: +1.00

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AudioEye Gets $20 Million Loan Facility From Bridge Bank
AudioEye Gets $20 Million Loan Facility From Bridge Bank
Apr 1, 2025
05:59 PM EDT, 04/01/2025 (MT Newswires) -- AudioEye ( AEYE ) said Tuesday it secured a $20 million loan facility from Bridge Bank, a division of Western Alliance Bancorporation (WAL). The facility comprises a $12 million term loan, expected to repay the company's existing 2023 term loan and bolster its cash position, according to AudioEye ( AEYE ). It added...
SEC, billionaire Winklevoss twins may resolve lawsuit over Gemini Earn
SEC, billionaire Winklevoss twins may resolve lawsuit over Gemini Earn
Apr 1, 2025
NEW YORK, April 1 (Reuters) - An exchange run by billionaire twins Tyler and Cameron Winklevoss may soon resolve a U.S. Securities and Exchange Commission lawsuit claiming they failed to register a cryptocurrency asset lending program before offering it to retail investors. In a joint letter filed on Tuesday in Manhattan federal court, the twins' Gemini Trust and the SEC...
Inventiva Completes Enrollment in Phase 3 Study of Liver Treatment
Inventiva Completes Enrollment in Phase 3 Study of Liver Treatment
Apr 1, 2025
05:57 PM EDT, 04/01/2025 (MT Newswires) -- Inventiva ( IVA ) completed the enrollment in a phase 3 clinical trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, a liver disease. Enrollment targets were exceeded with 1,009 patients in the main cohort and 410 patients in the exploratory cohort, the company said Tuesday in a statement. Completion of enrollment in...
Inhibrx Biosciences Signs Deal With Outgoing CSO Brendan Eckelman's New Venture
Inhibrx Biosciences Signs Deal With Outgoing CSO Brendan Eckelman's New Venture
Apr 1, 2025
06:00 PM EDT, 04/01/2025 (MT Newswires) -- Inhibrx Biosciences ( INBX ) said late Tuesday that Brendan Eckelman, its co-founder and chief scientific officer, will leave the company to form a private biotechnology firm that signed an exclusive license agreement with Inhibrx. The deal is for the rights to certain technologies no longer being pursued by Inhibrx. The pact includes...
Copyright 2023-2026 - www.financetom.com All Rights Reserved